At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 153 enrolled
Drug / intervention
OP-1250drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer
In Brief
A Phase 2 clinical trial evaluating OP-1250 for Hormone Receptor Positive Breast Carcinoma and HER2-negative Breast Cancer. Completed, enrolled 153 participants across 19 sites in 2 countries.
Detailed Summary
This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor (HR)-positive, her2-negative breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartAug 2020
Primary CompletionJul 2024
TodayJul 2026
First PostedAug 10, 2020
Enrollment StartAug 13, 2020
Primary CompletionJul 30, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 5.9 years ago
Interventions
OP-1250drug
Complete Estrogen Receptor ANtagonist (CERAN)